natgillin/translations-raw huggingface dataset:
The most commonly reported side effects with Senshio (affecting up to 1 in 10 people) are vulvovaginal candidiasis and other mycotic (fungal) infections, hot flushes, muscle spasms, vaginal and genital discharge, and rash.
Najčešće nuspojave lijeka Senshio (mogu se javiti u više od 1 na 10 osoba) su vulvovaginalna kandidiaza i druge mikotične (gljivične) infekcije, navale vrućine, mišićni spazmi, vaginalni i genitalni iscjedak i osip.
The most commonly reported treatment related adverse reactions reported during the pivotal clinical trials were constipation and symptoms commonly associated with drug withdrawal (i.e. insomnia, headache, nausea, hyperhidrosis and pain).
Najčešće prijavljene nuspojave vezane uz liječenje, zabilježene tijekom ključnih kliničkih ispitivanja su konstipacija i simptomi često povezani s ustezanjem lijeka (npr. nesanica, glavobolja, mučnina, hiperhidroza i bol).
The most commonly reported undesirable effects related to pemetrexed, whether used as monotherapy or in combination, are bone marrow suppression manifested as anaemia, neutropenia, leukopenia, thrombocytopenia; and gastrointestinal toxicities, manifested as anorexia, nausea, vomiting, diarrhoea, constipation, pharyngitis, mucositis, and stomatitis.
Najčešće prijavljivane nuspojave povezane s pemetreksedom, kako u monoterapiji tako i u kombinaciji s drugim lijekovima, su supresija koštane srži koja se očituje kao anemija, neutropenija, leukopenija trombocitopenija; i gastrointestinalna toksičnost, koja se očituje kao anoreksija, mučnina, povraćanje, proljev, konstipacija, faringitis, mukozitis i stomatitis.
The most commonly reported were vitreous floaters, eye pain and photopsia, as well as conjunctival haemorrhage resulting from the injection procedure.
Najčešće su prijavljivani opaciteti u staklovini, bol u oku i fotopsija, kao i krvarenje u spojnicu uzrokovano postupkom davanja injekcije.
The most effective method to remove lactate and metformin is haemodialysis.
Najučinokovitija metoda uklanjanja laktata i metformina je hemodijaliza.
The most frequent (≥1%) ADRs leading to discontinuation of one or more components of FOLFIRI were: neutropenia (12.5%), thrombocytopenia (4.2%), diarrhoea (2.3%) and stomatitis (2.3%).
Najčešće nuspojave (≥ 1%) koje su dovele do prekida primjene jedne ili više sastavnica protokola FOLFIRI bile su: neutropenija (12,5%), trombocitopenija (4,2%), proljev (2,3%) i stomatitis (2,3%).
The most frequent (≥10%) non-haematological adverse reactions were rash, pruritus, headache, nausea, fatigue, alopecia, myalgia and upper abdominal pain.
Najčešće (≥10%) nehematološke nuspojave bile su osip, svrbež, glavobolja, mučnina, umor, alopecija, mijalgija i bol u gornjem dijelu trbuha.
The most frequent ADRs seen in patients treated with Tarceva in studies BO18192 and BO25460 were rash and diarrhoea (see Table 2).
Najčešće nuspojave uočene u bolesnika liječenih lijekom Tarceva u ispitivanjima BO18192 i BO25460 bile su osip i proljev (vidjeti Tablicu 2).
The most frequent ADRs seen in patients treated with Tarceva in study ML20650 were rash and diarrhoea (any Grade 80% and 57%, respectively), most were Grade 1/2 in severity and manageable without intervention.
Najčešće nuspojave u bolesnika liječenih lijekom Tarceva u ispitivanju ML 20650 bile su osip i proljev (bilo kojeg stupnja 80% odnosno 57%); po ozbiljnosti većina je bila Stupnja 1/2 te nisu zahtijevale intervenciju.
The most frequent ADRs were diarrhoea and skin related adverse events (see section 4.4) as well as stomatitis and paronychia (see also Table 3 and 4).
Najčešće nuspojave na lijek bile su proljev i nuspojave povezane s kožom (vidjeti dio 4.4) kao i stomatitis, te paronihija (vidjeti također tablicu 3 i 4).
The most frequent adverse drug reactions (> 10.0% of patients) during treatment with SIRTURO in the controlled trials were nausea (35.3% in the SIRTURO group vs 25.7% in the placebo group), arthralgia (29.4% vs 20.0%), headache (23.5% vs 11.4%), vomiting (20.6% vs 22.9%) and dizziness (12.7% vs 11.4%).
Najčešće nuspojave (> 10,0% bolesnika) u kontroliranim ispitivanjima tijekom liječenja lijekom SIRTURO bile su mučnina (35,3% u SIRTURO skupini naspram 25,7% u placebo skupini), artralgija (29,4% naspram 20,0%), glavobolja (23,5% naspram 11,4%), povraćanje (20,6% naspram 22,9%) i omaglica (12,7% naspram 11,4%).
The most frequent adverse drug reactions (ADRs) were: headache, nausea, abdominal pain, rash, arthralgia, backpain, pain at extremity, flushing, pyrexia, infusion site reactions, blood pressure increased, oxygen saturation decreased, tachycardia and chills.
Najčešće nuspojave bile su: glavobolja, mučnina, bol u abdomenu, osip, artralgija, bol u leđima, bol u ekstremitetima, crvenilo praćeno osjećajem užarenosti, pireksija, alergijske reakcije na mjestu infuzije, povišen krvni tlak, smanjena zasićenost kisikom, tahikardija i zimica.
The most frequent adverse events in the bosentan- and the placebo-treated patients were, respectively, anaemia or haemoglobin decrease (7 and 2 patients), generalised oedema (3 and 0 patients), and vomiting (2 and 0 patients).
Najčešći štetni događaji u bolesnika koji su primali bosentan i placebo bili su: anemija ili smanjenje razine hemoglobina (u 7 odnosno 2 bolesnika), generalizirani edem (u 3 odnosno 0 bolesnika) i povraćanje (u 2 odnosno 0 bolesnika).
The most frequent adverse reaction during treatment with NeoRecormon is an increase in blood pressure or aggravation of existing hypertension, especially in cases of rapid PCV increase (see section 4.4).
Tijekom liječenja lijekom NeoRecormon najčešća nuspojava je porast krvnog tlaka ili pogoršanje postojeće hipertenzije, poglavito u slučajevima vrlo brzog porasta vrijednosti hematokrita (vidjeti dio 4.4).
The most frequent adverse reaction is “headache” reported in 34 % of patients.
Najčešća nuspojava je glavobolja koja je prijavljena u 34% bolesnika.
The most frequent adverse reaction reported for Gilenya 0.5 mg leading to treatment interruption was ALT elevations (2.2%).
Najčešća nuspojava prijavljena za Gilenyu od 0,5 mg koja je dovela do prekida liječenja bila je povišenje ALT (2,2%).
The most frequent adverse reactions (incidence ≥1/10 and suspected by the investigator to be related to treatment) from the pooled safety data are (in decreasing order): stomatitis, upper respiratory tract infections, amenorrhoea, hypercholesterolaemia, nasopharyngitis, acne, menstruation irregular, sinusitis, otitis media and pneumonia.
Najčešće nuspojave (incidencija ≥1/10 i za koje je ispitivač sumnjao da su povezane s liječenjem) iz objedinjenih sigurnosnih podataka su (prema padajućem redoslijedu): stomatitis, infekcije gornjeg dijela dišnog sustava, amenoreja, hiperkolesterolemija, nazofaringitis, akne, neredovita menstruacija, sinusitis, upala srednjeg uha i pneumonija.
The most frequent adverse reactions (incidence ≥10%) on Gilenya 0.5 mg were influenza, sinusitis, headache, diarrhoea, back pain, hepatic enzyme increased and cough.
Najčešće nuspojave (incidencija ≥10%) uz Gilenyu od 0,5 mg bile su gripa, sinusitis, glavobolja, proljev, bol u leđima, povišenje jetrenih enzima i kašalj.
The most frequent adverse reactions (≥3%, all-causality frequency) associated with dosing interruptions were neutropenia (11%), elevated transaminases (7%), vomiting (5%), and nausea (4%).
Najčešće nuspojave (≥3%, učestalost svih uzroka) povezane s prekidom primjene lijeka bile su neutropenija (11 %), povišene transaminaze (7%), povraćanje (5%) i mučnina (4%).
The most frequent adverse reactions are headache (11.5%), oedema/fluid retention (13.2%), abnormal liver function test (10.9%) and anaemia/haemoglobin decrease (9.9%).
Najčešće nuspojave bile su glavobolja (11,5%), edem/zadržavanje tekućine (13,2%), promijenjeni nalazi jetrene funkcije (10,9%) i anemija/snižene vrijednosti hemoglobina (9,9%).
The most frequent adverse reactions are headache (11.5%), oedema/fluid retention (13.2%), abnormal liver function test (10.9%) and anaemia/haemoglobin decrease (9.9%).
Najčešće nuspojave bile su glavobolja (11,5%, edem/zadržavanje tekućine (13,2%, promijenjeni nalazi jetrene funkcije (10,9% i anemija/snižene vrijednosti hemoglobina (9,9%).
The most frequent adverse reactions are musculoskeletal pains such as bone pain and myalgia.
Najčešće nuspojave su mišićno-koštani bolovi poput bolova u kostima i mialgije.
The most frequent adverse reactions considered due to receipt of MabThera IRRs.
Najčešće nuspojave koje se smatraju posljedicom primjene lijeka MabThera bile su reakcije povezane s infuzijom.
The most frequent adverse reactions leading to permanent discontinuation in ≥1% of patients treated with the ZALTRAP/FOLFIRI regimen were vascular disorders (3.8%) including hypertension (2.3%), infections (3.4%), asthenia/fatigue (1.6%, 2.1%),diarrhoea (2.3%), dehydration (1%), stomatitis (1.1%), neutropenia (1.1%), proteinuria (1.5%), and pulmonary embolism (1.1%).
Najčešće nuspojave koje su dovele do trajnog prekida liječenja u ≥ 1% bolesnika liječenih protokolom ZALTRAP/FOLFIRI bili su vaskularni poremećaji (3,8%), uključujući hipertenziju (2,3%), infekcije (3,4%), astenija/umor (1,6%, 2,1%), proljev (2,3%), dehidracija (1%), stomatitis (1,1%), neutropenija (1,1%), proteinurija (1,5%) i plućna embolija (1,1%).
The most frequent adverse reactions leading to withdrawal for liraglutide­treated patients were nausea (2.8% of patients) and vomiting (1.5%).
Najčešće nuspojave koje su dovele do prestanka primjene lijeka u bolesnika liječenih liraglutidom bile su mučnina (2,8% bolesnika) i povraćanje (1,5%).
The most frequent adverse reactions observed during the treatment of hepatic VOD in pre-marketing use are haemorrhage (including but not limited to gastrointestinal haemorrhage, pulmonary haemorrhage and epistaxis), hypotension and coagulopathy.
Najčešće nuspojave opažene tijekom liječenja veno-okluzivne bolesti jetre u primjeni lijeka prije stavljanja u promet bile su hemoragija (uključujući ali ne ograničavajući se samo na gastrointestinalnu hemoragiju, plućnu hemoragiju i epistaksu), hipotenzija i koagulopatija.
The most frequent adverse reactions observed with dronedarone 400 mg twice daily in the 5 studies were diarrhoea, nausea and vomiting, fatigue and asthenia.
Najčešće nuspojave primijećene kod primjene dronedarona u dozi od 400 mg dvaput na dan u 5 ispitivanja bile su proljev, mučnina i povraćanje, umor i astenija.
The most frequent adverse reactions of any grade (experienced by at least 25% of patients) included diarrhoea (74%), fatigue (56%), nausea (50%), decreased appetite (46%), palmar-plantar erythrodysaesthesia syndrome (PPES) (42%), hypertension (37%), vomiting (32%), weight decreased (31%), and constipation (25%).
Najčešće nuspojave bilo kojeg stupnja (nuspojave koje su se javile u najmanje 25 % bolesnika) uključuju proljev (74 %), umor (56 %), mučninu (50 %), smanjeni apetit (46 %), sindrom palmarno-plantarne eritrodizestezije (PPES) (42 %), hipertenziju (37 %), povraćanje (32 %), smanjenje tjelesne težine (31 %) i konstipaciju (25 %).
The most frequent adverse reactions reported in clinical trials were fever, nausea, vomiting, fatigue, arrhythmia, chills, pain, wound infection and skin reaction.
Najčešće nuspojave prijavljene u kliničkim ispitivanjima bile su vrućica, mučnina, povraćanje, umor, aritmija, zimica, bolovi, infekcija rane i kožne reakcije.
The most frequent adverse reactions reported in the paediatric population were ocular hyperaemia (16.9%) and growth of eyelashes (6.5%).
Najčešće zabilježene nuspojave u pedijatrijskoj populaciji bile su okularna hiperemija (16,9%) i rast trepavica (6,5 %).
The most frequent adverse reactions reported with silodosin in placebo controlled clinical studies and during long-term use were ejaculatory disorders such as retrograde ejaculation and anejaculation (ejaculatory volume reduced or absent), with a frequency of 23 %.
Najčešće nuspojave zabilježene uz silodozin u placebom kontroliranim kliničkim ispitivanjima i za vrijeme dugotrajnog uzimanja bile su poremećaji ejakulacije, kao što je retrogradna ejakulacija i izostanak ejakulacije (smanjen volumen ejakulata ili izostanak ejakulata) s učestalosti od 23 %.
The most frequent adverse reactions reported with the use of this medicinal product in female partners were vulvovaginal burning sensation (3.9%), and genital hypoaesthesia (1.0%).
Najčešće nuspojave koje su prijavljene u vezi s primjenom ovog lijeka u ženskih partnerica bili osjet pečenja u vulvovaginalnom području (3,9 %) i genitalna hipoestezija (1,0 %).
The most frequent finding in repeat-dose studies consisted of increased primary spongiosa in the metaphyses of long bones in growing animals at nearly all doses, a finding that reflected the compound's pharmacological antiresorptive activity.
Najčešći nalaz u ispitivanjima ponovljenih doza bio je povećana primarna spongioza u metafizama dugih kostiju životinja u razvoju kod gotovo svih doza, što je odraz farmakološke antiresorptivne aktivnosti tvari.
The most frequent finding in repeat-dose studies consisted of increased primary spongiosa in the metaphyses of long bones in growing animals at nearly all doses, a finding that reflected the compound's pharmacological antiresorptive activity.
Najčešći nalaz u ispitivanjima ponovljenih doza bio je povećana primarna spongioza u metafizama dugih kostiju životinja u razvoju kod gotovo svih doza, što je odraz farmakološkog antiresorptivne aktivnosti tvari.
The most frequent finding in repeat-dose studies consisted of increased primary spongiosa in the metaphyses of long bones in growing animals at nearly all doses, a finding that reflected the compound’s pharmacological antiresorptive activity.
Najčešći nalaz u ispitivanjima ponovljene doze bio je povećana primarna spongioza u metafizama dugih kostiju životinja u razvoju kod gotovo svih doza, što je odraz farmakološkog antiresorptivnog djelovanja spoja.
The most frequent finding in the repeat-dose studies consisted of increased primary spongiosa in the metaphyses of long bones in growing animals at nearly all doses, a finding that reflected the compound's pharmacological antiresorptive activity.
Najčešći nalaz u ispitivanjima s ponovljenim dozama sastojao se od povećanog primarnog spongioznog tkiva u metafizama dugih kostiju kod životinja u razvoju pri gotovo svim dozama, nalaz koji je odražavao farmakološko antiresorpcijsko djelovanje tvari.
The most frequent finding in the repeat-dose studies consisted of increased primary spongiosa in the metaphyses of long bones in growing animals at nearly all doses, a finding that reflected the compound’s pharmacological antiresorptive activity.
Najčešći nalaz u ispitivanjima s ponovljenim dozama bio je povećano primarno spongiozno tkivo u metafizama dugih kostiju kod životinja u razvoju i to pri gotovo svim dozama, odnosno nalaz koji je odražavao farmakološko antiresorpcijsko djelovanje kemijskog spoja.
The most frequent finding in the repeat-dose studies consisted of increased primary spongiosa in the metaphyses of long bones in growing animals at nearly all doses, a finding that reflected the compound’s pharmacological antiresorptive activity.
Najčešći nalaz u ispitivanjima s ponovljenim dozama sastojao se od povećanog primarnog spongioznog tkiva u metafizama dugih kostiju kod životinja u razvoju pri gotovo svim dozama, nalaz koji je odražavao farmakološko antiresorpcijsko djelovanje lijeka.
The most frequent grade 3-4 adverse reactions (incidence ≥1%) were stomatitis, amenorrhoea, pneumonia, neutropenia, pyrexia, gastroenteritis viral and cellulitis.
Najučestalije nuspojave stupnja 3-4 (incidencija ≥1%) bile su stomatitis, amenoreja, pneumonija, neutropenija, pireksija, virusni gastroenteritis i celulitis.
The most frequent injection site reactions were injection site erythema, injection site pain and injection site bruising.
Najčešće reakcije na mjestu primjene su eritem, bol i modrice na mjestu primjene.
The most frequent of adverse events reported in excess of placebo were fatigue (1.2 %), dry mouth (0.8 %) and headache (0.6 %).
Najčešće prijavljene nuspojave kod primjene lijeka, a koje su češće u odnosu na placebo, bile su umor (1,2%), suha usta (0,8%) i glavobolja (0,6%).
The most frequent reported or observed serious adverse drug reactions were:
Najčešće prijavljene ili opažene ozbiljne nuspojave bile su:
The most frequent serious and fatal adverse reactions are major haemorrhage (access site and non access-site bleeding, including intracranial haemorrhage) and hypersensitivity, including anaphylactic shock.
Najčešće ozbiljne i smrtonosne nuspojave su veliko krvarenje (krvarenje na pristupnom mjestu i krvarenje koje nije na pristupnom mjestu, uključujući intrakranijalno krvarenje) i preosjetljivost uključujući anafilaktički šok.
The most frequent side effects in patients receiving Xofigo (very common [may affect more than 1 in 10 people]) are:
Najčešće opažene nuspojave u bolesnika koji primaju Xofigo (vrlo često [mogu se javiti u više od 1 na 10 osoba]) su:
The most frequent side effects include peripheral sensory or motor neuropathy, tiredness, nausea (feeling sick), diarrhoea, neutropenia, vomiting, fever, infections and cough.
Najčešće su nuspojave periferna senzorna ili motorna neuropatija, umor, mučnina (osjećaj slabosti), proljev, neutropenija, povraćanje, vrućica, infekcije i kašalj.
The most frequent side effects of INTELENCE are rash, diarrhoea, nausea, and headache (see section ‘4.
Najčešće nuspojave INTELENCEa su osip, proljev, mučnina i glavobolja (pogledajte dio ‘4.
The most frequent side effects with Edurant (seen in more than 1 patient in 10) are headache, insomnia, dizziness, nausea (feeling sick), and increased levels of total cholesterol, low-density- lipoprotein (LDL) cholesterol, pancreatic amylase (an enzyme produced in the pancreas that breaks down starch into sugars) and transaminases (liver enzymes).
Najčešće nuspojave lijeka Edurant (prijavljene kod više od 1 na 10 osoba) su glavobolja, nesanica, vrtoglavica, mučnina (osjećaj slabosti) i povišene razine ukupnog kolesterola, lipoproteinskog kolesterola niske gustoće (LDL), gušteračne amilaze (enzima koji se proizvodi u gušterači, a razgrađuje škrob u šećere) i transaminaza (jetrenih enzima).
The most frequent side effects with Eliquis (seen in between 1 and 10 patients in 100) are anaemia (low red blood cell counts), haemorrhage (bleeding), haematoma (a collection of blood under the skin), contusion (bruising) and nausea (feeling sick) when Eliquis is used for prevention of venous thromboembolism.
Najčešće nuspojave Eliquis (mogu se javiti u između 1 do 10 na 100 osoba) su anemija (nizak broj crvenih krvnih stanica), hemoragija (krvarenje), hematom (nakupljanje krvi ispod kože), kontuzija (podljev) i mučnina (osjećaj slabosti) u slučaju kada se Eliquis koristi za prevenciju venske tromboembolije.
The most frequent treatment-related adverse reaction was eye pain, reported at an overall incidence of 0.7%.
Najčešće prijavljivana nuspojava, povezana s uzimanjem lijeka, bila je bol u oku, čija je ukupna incidencija iznosila 0,7 %.
The most frequent treatment-related adverse reactions reported in the two phase II and one phase III trials in patients with transitional cell carcinoma of the urothelium (450 patients treated with vinflunine) were haematological disorders, mainly neutropenia and anaemia; gastrointestinal disorders, especially constipation, anorexia, nausea, stomatitis/mucositis, vomiting, abdominal pain and diarrhoea, and general disorders such as asthenia/fatigue.
Najčešće nuspojave povezane s liječenjem prijavljene u dva ispitivanja faze II i jednom ispitivanju faze III u bolesnika s karcinomom prijelaznih stanica urotela (450 bolesnika liječenih vinfluninom) bili su hematološki poremećaji, uglavnom neutropenija i anemija; poremećaji probavnog sustava, osobito konstipacija, anoreksija, mučnina, stomatitis/mukozitis, povraćanje, bol u abdomenu i proljev i opći poremećaji kao što su astenija/umor.
The most frequent undesirable effects are musculoskeletal pains.
Najčešće su nuspojave mišićno-koštani bolovi.
The most frequently (> 25% of subjects) detected post-baseline RAVs in these subjects were amino acid substitutions V36M (61%) and R155K (68%) in subjects infected with genotype 1a viruses and T54A (42%), T54S (37%), A156S (26%) and V170A (32%) in subjects infected with genotype 1b viruses.
Najčešći RAV-ovi otkriveni u tih ispitanika nakon početka ispitivanja (otkriveni u > 25% ispitanika) bili su V36M (61%) i R155K (68%) u ispitanika zaraženih virusom genotipa 1a, te T54A (42%), T54S (37%), A156S (26%) i V170A (32%) u ispitanika zaraženih virusom genotipa 1b.
The most frequently (seen in ≥ 1 % of patients) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism, leukopenia, neutropenia (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic aminotransferases (see section 4.4), rash, asthenia, fatigue, pyrexia, arthralgia, increased alkaline phosphatase, high gamma glutamyltransferase, high uric acid, high creatine phosphokinase and oedema.
Najčešće zabilježene nuspojave (uočene u ≥1 % bolesnika) povezane s primjenom olanzapina u kliničkim ispitivanjima bile su somnolencija, povećanje tjelesne težine, eozinofilija, povišene vrijednosti prolaktina, kolesterola, glukoze i triglicerida (vidjeti dio 4.4), glukozurija, povećan apetit, omaglica, akatizija, parkinsonizam, leukopenija, neutropenija (vidjeti dio 4.4), diskinezija, ortostatska hipotenzija, antikolinergički učinci, prolazni asimptomatski porast vrijednosti jetrenih aminotransferaza (vidjeti dio 4.4), osip, astenija, umor, pireksija, artralgija, povišena razina alkalne fosfataze, visoka razina gama glutamiltransferaze, visoka razina mokraćne kiseline, visoka razina kreatin fosfokinaze i edem.
The most frequently (seen in ≥ 1 % of patients) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism, leukopenia, neutropenia (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepaticaminotransferases (see section 4.4), rash, asthenia, fatigue, pyrexia, arthralgia, increased alkaline phosphatase, high gamma glutamyltransferase, high uric acid, high creatine phosphokinase and oedema.
Najčešće prijavljene nuspojave (uočene u ≥1% bolesnika) povezane s primjenom olanzapina u kliničkim ispitivanjima bile su somnolencija, povećanje tjelesne težine, eozinofilija, povišene vrijednosti prolaktina, kolesterola, glukoze i triglicerida (vidjeti dio 4.4), glikozurija, povećan apetit, omaglica, akatizija, parkinsonizam, leukopenija, neutropenija (vidjeti dio 4.4), diskinezija, ortostatska hipotenzija, antikolinergički učinci, prolazni asimptomatski porast vrijednosti jetrenih aminotransferaza (vidjeti dio 4.4), osip, astenija, umor, pireksija, artralgija, povišena razina alkalne fosfataze, visoka razina gama glutamiltransferaze, visoka razina mokraćne kiseline, visoka razina kreatin fosfokinaze i edem.